BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

Background: Immunotherapy-based treatments have demonstrated high efficacy in patients with advanced and locally advanced non-small-cell lung cancer (NSCLC). BRAF mutations affect a small but significant fraction of NSCLC. The efficacy of these therapies in this subgroup of patients is unknown. Mate...

Descripción completa

Detalles Bibliográficos
Autores: Provencio Pulla, Mariano|||0000-0001-6315-7919, Nadal, Ernest|||0000-0002-9674-5554, González Larriba, José Luis|||0000-0003-2631-0309, Insa, Amelia|||0000-0002-3438-6170, Sánchez Hernández, Alfredo|||0000-0001-5826-8390, Del Rosario García-Campelo, María|||0000-0003-2113-1504, Rogado, J., Martinez-Marti, Alex|||0000-0002-6714-9526, Bosch-Barrera, J.|||0000-0002-0893-7821, Bernabé, Reyes|||0000-0003-0312-9195, Ponce, S., Reguart, Noemi|||0000-0001-8190-499X, Dómine Gómez, Manuel|||0000-0003-1634-9832, Aguilar, Alba, Majem Tarruella, Margarita|||0000-0002-9919-7485, Estival, Anna|||0000-0002-2788-9159, Cobo, Manuel|||0000-0003-3402-1144, Camps, Carlos|||0000-0002-0648-5403, Calvo, Virginia|||0000-0002-3503-4847, Collazo-Lorduy, Ana, Cruz-Bermúdez, Alberto|||0000-0001-5136-7011, Romero, A., Robado de Lope, Lucía, Serna-Blasco, Roberto, Diz Taín, Pilar|||0000-0003-4284-3965, Massuti, Bartomeu|||0000-0002-6247-4493, Casal-Rubio, Joaquín, Sequero López, S., Vázquez Estévez, S., de Castro, J., Coves Sarto, J., Peña Cabia, Silvia, López Martín, A., Sala González, María Ángeles, Barneto Aranda, Isidoro|||0000-0001-6302-1034
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:324022
Acceso en línea:https://ddd.uab.cat/record/324022
https://dx.doi.org/urn:doi:10.1016/j.lungcan.2024.107865
Access Level:acceso abierto
Palabra clave:BRAF
Immunotherapy
NSCLC
Descripción
Sumario:Background: Immunotherapy-based treatments have demonstrated high efficacy in patients with advanced and locally advanced non-small-cell lung cancer (NSCLC). BRAF mutations affect a small but significant fraction of NSCLC. The efficacy of these therapies in this subgroup of patients is unknown. Materials and methods: Plasma and tissue samples from 116 resectable stage IIIA/B NSCLC patients, included in NADIM and NADIM II clinical trials (NADIM cohort), and from a prospective academic cohort with 84 stage IV NSCLC patients (BLI-O cohort), were analyzed by next-generation sequencing. Results: The p.G464E, p.G466R, p.G466V, p.G469V, p.L597Q, p.T599I, p.V600E (n = 2) BRAF mutations, were identified in four (3.45 %) samples from the NADIM cohort, all of which were cases treated with neoadjuvant chemoimmunotherapy (CH-IO), and four (4.76 %) samples from the BLI-O cohort, corresponding to cases treated with first-line immunotherapy (n = 2) or CH-IO (n = 2). All these patients were alive and had no evidence of disease at data cut-off. Conversely, patients with BRAF wild-type (wt) tumors in the BLI-O cohort had a median progression-free survival (PFS) of 5.49 months and a median overall survival (OS) of 12.00 months (P-LogRank = 0.013 and 0.046, respectively). Likewise, PFS and OS probabilities at 36 months were 60.5 % and 76.1 % for patients with BRAF-wt tumors in the NADIM cohort. The pathological complete response (pCR) rate after neoadjuvant CH-IO in patients with BRAF-positive tumors (n = 4) was 100 %, whereas the pCR rate in the BRAF-wt population was 44.3 % (RR: 2.26; 95 % CI: 1.78-2.85; P < 0.001). Conclusion: BRAF mutations may be a good prognostic factor for advanced and locally advanced NSCLC patients undergoing immunotherapy-based treatments.

Similares en LA Referencia